NCT06818682View on ClinicalTrials.gov

Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

January 1, 2035

Study Completion Date

January 1, 2035

Conditions
Prostate Carcinoma
Interventions
DRUG

ADT for 9 months and ARTA for 6 months

Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 9 months and ARTA for 6 months

DRUG

ADT for 2 years

Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 2 years

Trial Locations (1)

400012

RECRUITING

Tata Memorial Centre, Mumbai

All Listed Sponsors
lead

Tata Memorial Centre

OTHER